Journal: bioRxiv
Article Title: Oviduct fluid metabolic regulation of embryonic genome methylation
doi: 10.1101/2025.06.13.659599
Figure Lengend Snippet: ( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD) supplementation; or ( iii ) methanol (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
Article Snippet: These were: ( a ) negative control – comprising Base Medium ( Table S2 ); ( b ) E2 – Base Medium supplemented with E2 (Thermo Scientific Chemicals, L0380103) dissolved in methanol (Fisher Chemical, A4521) at a final concentration of 50 nM with a corresponding vehicle contribution of 0.6 % ( v / v ); ( c ) MPA – Base Medium supplemented with MPA (Thermo Scientific Chemicals, 461120010) dissolved in methanol at a final concentration of 1 µM with a corresponding vehicle contribution of 0.3 % ( v / v ); ( d ) Physiological mimic – Base Medium supplemented with both E2 and MPA as above, with a corresponding cumulative vehicle contribution of 0.9 % ( v / v ); ( e ) Pathological mimic – Base Medium supplemented with E2 and MPA as above, in addition to THC (Cayman Chemical, ISO60157) dissolved in methanol at a final concentration of 6 µM with a corresponding vehicle contribution of 0.2 % ( v / v ); and CBD (Cayman Chemical, ISO60156) dissolved in methanol at a final concentration of 6 µM with a corresponding vehicle contribution of 0.2 % ( v / v ); and ( f ) vehicle control – Base Medium supplemented with 1.3 % ( v / v ) methanol – identical to the largest solvent contribution (Group e ).
Techniques: In Vivo, Expressing, Control, Software, Generated